FIMASARTAN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H31N7OS
Molecular Weight	501.646
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCC1=NC(C)=C(CC(=S)N(C)C)C(=O)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=NN4

InChI

InChIKey=AMEROGPZOLAFBN-UHFFFAOYSA-N

InChI=1S/C27H31N7OS/c1-5-6-11-24-28-18(2)23(16-25(36)33(3)4)27(35)34(24)17-19-12-14-20(15-13-19)21-9-7-8-10-22(21)26-29-31-32-30-26/h7-10,12-15H,5-6,11,16-17H2,1-4H3,(H,29,30,31,32)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22864732
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23811571, http://www.boryung.co.kr/eng/product/mainProduct.do

Fimasartan is a angiotensin II receptor antagonist which was developed in Korea for the treatment of hypertension. The drug is available in different forms: Kanarb, Dukarb (in combination with Amlodipine), Tuvero (in combination with Rosuvastatin). Fimasartan was tested to be effective in Mexican and Russian population and now is being tested in the USA.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Angiotensin II receptor 9 Target ID: CHEMBL2094256 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23811571	Antagonist 2778		0.13 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Essential hypertension 17 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22864732	Primary		Approved 8429	KANARB Approved Use For the treatment of essential hypertension. Launch Date 2010

PubMed

Title	Date	PubMed
Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers.	2011 Jun	21394036
Simultaneous determination of fimasartan, a novel antihypertensive agent, and its active metabolite in rat plasma by liquid chromatography-tandem mass spectrometry.	2011 Nov	21268050
Effect of age on the pharmacokinetics of fimasartan (BR-A-657).	2011 Nov	21950382
Fimasartan, a novel angiotensin II receptor antagonist.	2012 Jul	22864732
Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.	2012 Mar	22381711
Fimasartan, anti-hypertension drug, suppressed inducible nitric oxide synthase expressions via nuclear factor-kappa B and activator protein-1 inactivation.	2013	23449332
Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist.	2013	23811571
Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study.	2013 Feb	23344912
Influence of Fimasartan (a Novel AT(1) Receptor Blocker) on Catecholamine Release in the Adrenal Medulla of Spontaneously Hypertensive Rats.	2013 Feb	23441003
Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study.	2014	25336916
The Efficacy of Fimasartan for Cardiovascular Events and Metabolic Syndrome (K-MetS Study): Rationale, Design and Participant Characteristics.	2014 May	26587436
Cardioprotective effect of fimasartan, a new angiotensin receptor blocker, in a porcine model of acute myocardial infarction.	2015 Jan	25552881

Patents

Sample Use Guides

In Vivo Use Guide

Fimasartan is taken as a single oral dose of 60-mg tablet or a single 30-mg intravenous (IV) infusion.

Route of Administration: Other

In Vitro Use Guide

Rabbit thoracic aorta cells were incubated with different concentrations of fimasartan ((0.1, 1, 10 nM). At those concentrations fimasartan caused nonparallel rightward shifts in the concentration–contractile response curve to Ang II with a significant reduction in the maximal contractile response to 96.6, 47 and 18%, respectively.

Name

Type

Language

FIMASARTAN

Official Name

English

BR1015 component fimasartan

Common Name

English

fimasartan [INN]

Common Name

English

2-((2-BUTYL-4-METHYL-6-OXO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-1,6-DIHYDROPYRIMIDIN-5-YL))-N,N-DIMETHYLTHIOACETAMIDE

Systematic Name

English

Fimasartan [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

C09DA10